Condition: Breast Cancer · HER2-negative Breast Cancer · Hormone Receptor Positive Tumor · Sponsor: SOLTI Breast Cancer Research Group
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.
This description comes directly from the study's public registry record.
Sara Cano, PhD · + 34 933 436 302 · info@gruposolti.org
Juan M Ferrero, PharmD · + 34 933 436 302 · info@gruposolti.org
Always discuss trial participation with your own doctor first.
| ICO Badalona | Badalona, Barcelona, Spain | Recruiting |
| ICO Hospitalet | L'Hospitalet de Llobregat, Barcelona, Spain | Recruiting |
| Hospital Universitari Arnau de Vilanova de Lleida | Vilanova, Lleida, Spain | Recruiting |
| Hospital Universitario Virgen de la Arrixaca | El Palmar, Murcia, Spain | Recruiting |
| Hospital Universitario de Badajoz | Badajoz, Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Hospital Clinic de Barcelona | Barcelona, Spain | Recruiting |
| Complejo Hospitalario San Pedro de Alcántara | Cáceres, Spain | Recruiting |
| HM Sanchinarro (CIOCC) | Madrid, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Universitario Central de Asturias | Oviedo, Spain | Recruiting |
| Hospital Universitari Son Espases | Palma de Mallorca, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05982093